Our Impact

We follow a proven model, tailored to meet the needs of individual countries. Successful implementation involves understanding the scale of the problem, and designing a robust mass drug administration (MDA) campaign targeted to reach and treat the right people.

Measuring Success

We are committed to treating and eliminating these diseases that reinforce poverty. NTDs cause severe pain, long-term illness and even death for the millions of people infected. In children, infection leads to malnutrition, developmental problems and stunted growth. In adults, the ill effects of disease lead to social stigma, low self-esteem and a loss of productivity. NTDs persist in impoverished communities where people have limited protection from insects and animals that spread disease, and where access to medical care and prevention education is extremely limited.

The success of the END Fund will be measured by the reduction in infection rates to the level that the five diseases are no longer deemed a significant health concern. In addition to a reduction in disease burden, this will also result in improved quality of life for those treated.

Other factors include:

  • Community benefits in health education.
  • Enhanced government capacity through close monitoring, drug distribution, project management, data collection, data and laboratory research and analysis.
  • Educational measurements through decreased school absenteeism.
  • Economic measures through improvement of family livelihoods, increased per capita earning and cost benefit analysis for drug delivery.
  • Microfilaria prevalence has been brought down to levels needed to interrupt disease transmission.

By continually measuring progress, we can quickly address challenges and divert under-performing resources to where they yield the highest return on investment.